On Saturday, President Donald Trump signed an executive order to expedite research into ibogaine, a psychedelic compound, to address PTSD and traumatic brain injuries among veterans. This order directs the Food and Drug Administration (FDA) to revise its regulatory framework, facilitating clinical trials for ibogaine and other psychedelics, including psilocybin and MDMA. Currently classified as a Schedule I controlled substance in the United States, ibogaine has shown potential in alleviating mental health challenges, particularly for veterans. Studies suggest it may help mitigate addiction and PTSD symptoms, with emerging evidence indicating that it can enhance cognitive function in veterans suffering from traumatic brain injuries. Researchers at Stanford Medicine have found that ibogaine, when combined with magnesium, can significantly improve mental health outcomes. Dr. Nolan Williams noted that ibogaine's effects on brain activity could promote neuroplasticity, offering hope for veterans facing debilitating conditions. The executive order aims to eliminate legal barriers to comprehensive studies of ibogaine, potentially leading to breakthrough treatments for those in need.